Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 14, 2025, serves as a transaction notification for Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The report details share acquisitions executed on April 10 and April 11, 2025, resulting from the automatic re-investment of dividends paid to shareholders on April 10, 2025.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific share transaction data:
- Instrument Types: American Depositary Shares (ADSs) and Ordinary Shares (31 1/2 pence each).
- Transaction Price (ADSs): $34.1210 per share.
- Transaction Price (Ordinary Shares): £13.0668 per share.
- Transaction Volumes: Ranged from 10 ADSs to 12,698.763 Ordinary Shares per individual transaction.
- Trading Venues: New York Stock Exchange (XNYS) for ADSs; London Stock Exchange (XLON) for Ordinary Shares.
Material Changes
The filing does not provide comparative financial data or discuss material changes in the company's business operations, financial condition, or results of operations versus prior periods. The only changes reported are the incremental increases in shareholdings for the listed individuals due to dividend re-investment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is a statutory disclosure of routine equity transactions.
Important Facts for Investors
- Transaction Nature: All reported transactions are acquisitions via dividend re-investment, not open-market purchases or sales.
- Participants: Includes the CEO (Emma Walmsley), Chief Scientific Officer (Tony Wood), and multiple Independent Non-Executive Directors.
- Share Price Reference: The filing establishes the market price of GSK ADSs at approximately $34.12 and Ordinary Shares at approximately £13.07 as of the transaction dates.
- Compliance: These are initial notifications of transactions required under securities regulations for PDMRs.